20/20 Biolabs Inc (AIDX): Next-Year EPS Estimate 26.92%
As of 2026-11-12, 20/20 Biolabs Inc (AIDX) has a next-year EPS growth estimate of 26.92%. Featured in our EPS revision report on 2026-10-10.
Analyst estimates for AIDX have remained steady in the most recent observable window, with next-year EPS growth projected at 26.92%. Current-year growth stands at 31.58%.
What's Driving This
AIDX has been rising primarily because its next-year EPS growth estimate was revised to 26.92% on 2026-10-05 and remains at that level, signaling a structural uplift in expected profitability. No recent news headlines are available that tie this move to an earnings beat, contract win, guidance raise, or product launch. With the estimate holding steady since the initial flag, the upward trend appears to reflect continued momentum from that revision rather than a new catalyst.
Generated 2026-10-12 from news as of 2026-10-12
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 26.92%
- EPS growth this year
- 31.58%
- EPS next quarter (est)
- -$0.14
- Last price
- $0.20
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 26.92% | 31.58% | -$0.14 | $0.20 |
| 2026-11-11 | 26.92% | 31.58% | -$0.14 | $0.22 |
| 2026-11-10 | 26.92% | 31.58% | -$0.14 | $0.20 |
| 2026-11-09 | 26.92% | 31.58% | -$0.14 | $0.20 |
| 2026-11-07 | 26.92% | 31.58% | -$0.14 | $0.20 |
| 2026-11-06 | 26.92% | 31.58% | -$0.14 | $0.20 |
| 2026-11-05 | 26.92% | 31.58% | -$0.14 | $0.19 |
| 2026-11-04 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-11-03 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-11-02 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-10-31 | 26.92% | 31.58% | -$0.14 | $0.21 |
| 2026-10-30 | 26.92% | 31.58% | -$0.14 | $0.21 |
| 2026-10-29 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-10-28 | 26.92% | 31.58% | -$0.14 | $0.25 |
| 2026-10-27 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-10-26 | 26.92% | 31.58% | -$0.14 | $0.23 |
| 2026-10-23 | 26.92% | 31.58% | -$0.14 | $0.24 |
| 2026-10-22 | 26.92% | 31.58% | -$0.14 | $0.25 |
| 2026-10-21 | 26.92% | 31.58% | -$0.14 | $0.27 |
| 2026-10-20 | 26.92% | 31.58% | -$0.14 | $0.26 |
| 2026-10-19 | 26.92% | 31.58% | -$0.14 | $0.26 |
| 2026-10-16 | 26.92% | 31.58% | -$0.14 | $0.26 |
| 2026-10-15 | 26.92% | 31.58% | -$0.14 | $0.28 |
| 2026-10-14 | 26.92% | 31.58% | -$0.14 | $0.31 |
| 2026-10-13 | 26.92% | 31.58% | -$0.14 | $0.35 |
| 2026-10-12 | 26.92% | 31.58% | -$0.14 | $0.37 |
| 2026-10-11 | 26.92% | 31.58% | -$0.14 | $0.38 |
| 2026-10-10 | 26.92% | 31.58% | -$0.14 | $0.38 |
| 2026-10-09 | 26.92% | 31.58% | -$0.14 | $0.38 |
| 2026-10-08 | 26.92% | 31.58% | -$0.14 | $0.38 |
Reports Featuring AIDX
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is 20/20 Biolabs Inc's next-year EPS growth estimate?▾
As of 2026-11-12, 20/20 Biolabs Inc (AIDX) has a next-year EPS growth estimate of 26.92%, based on analyst consensus.
What sector and industry does 20/20 Biolabs Inc belong to?▾
20/20 Biolabs Inc operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AIDX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. 20/20 Biolabs Inc (AIDX) appears here because it was detected by our daily top-EPS-revision-performer screen.